EP 236: Fixing access and design in rare disease drug development with experts and patient advocates

Value of the Information & Strength of the Argument

The value of the information is high, as it provides firsthand perspectives from a patient who underwent gene therapy, a parent who lost a child to a rare disease, and an industry expert in clinical research. The discussion offers practical insights into the barriers to access, such as high costs and trial design issues, and emphasizes the need for early and continuous patient engagement. The argumentation is solid, with panelists building on each other’s points and providing concrete examples, such as the failure of therapies due to lack of patient input. However, the arguments are largely anecdotal and opinion-based, lacking empirical data or formal citations, which slightly weakens the overall rigor.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is moderate; the panelists are credible and experienced, but the discussion is conversational and lacks formal references. The sources cited are primarily personal experiences and general knowledge, with no specific studies or reports mentioned. The title accurately reflects the content, which is a panel discussion on improving access and design in rare disease drug development. The content aligns with the title, covering key aspects such as patient engagement, trial design, and access. No comments were provided for analysis.

The title accurately reflects the content: a panel discussion on improving access and design in rare disease drug development, featuring experts and patient advocates.

8/10

The discussion features credible experts and patient advocates with direct experience in rare disease drug development, including a CRISPR gene therapy trial participant. The content is grounded in real-world examples and aligns with current challenges in the field. However, it is primarily opinion-based and lacks formal citations or data, which slightly reduces the score.

• 00:00Intro to The Genetics Podcast
• 01:00Welcome to guests and what Rare Disease Day means to them
• 08:25Balancing hope with funding, pricing, and access in advanced therapies
• 12:13Why patient access must be built into drug development from day one
• 15:00Patient engagement, community readiness, and the realities of trial participation
• 18:26Why early patient input is still inconsistent and often treated as a checkbox
• 24:03Designing trials around what actually matters to patients and families
• 27:42Navigating regulators, payers, and trial design constraints in rare disease therapies
• 37:14Redefining success in gene therapy around access, scalability, and real patient benefit
• 45:04Closing remarks